1. Home
  2. SLQT vs MLYS Comparison

SLQT vs MLYS Comparison

Compare SLQT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLQT
  • MLYS
  • Stock Information
  • Founded
  • SLQT 1999
  • MLYS 2019
  • Country
  • SLQT United States
  • MLYS United States
  • Employees
  • SLQT N/A
  • MLYS N/A
  • Industry
  • SLQT Specialty Insurers
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLQT Finance
  • MLYS Health Care
  • Exchange
  • SLQT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • SLQT 386.9M
  • MLYS 1.0B
  • IPO Year
  • SLQT 2020
  • MLYS 2023
  • Fundamental
  • Price
  • SLQT $2.39
  • MLYS $14.54
  • Analyst Decision
  • SLQT Hold
  • MLYS Strong Buy
  • Analyst Count
  • SLQT 2
  • MLYS 4
  • Target Price
  • SLQT $3.38
  • MLYS $27.00
  • AVG Volume (30 Days)
  • SLQT 898.0K
  • MLYS 879.7K
  • Earning Date
  • SLQT 05-12-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • SLQT N/A
  • MLYS N/A
  • EPS Growth
  • SLQT N/A
  • MLYS N/A
  • EPS
  • SLQT N/A
  • MLYS N/A
  • Revenue
  • SLQT $1,488,701,000.00
  • MLYS N/A
  • Revenue This Year
  • SLQT $17.72
  • MLYS N/A
  • Revenue Next Year
  • SLQT $13.05
  • MLYS N/A
  • P/E Ratio
  • SLQT N/A
  • MLYS N/A
  • Revenue Growth
  • SLQT 20.41
  • MLYS N/A
  • 52 Week Low
  • SLQT $1.62
  • MLYS $8.24
  • 52 Week High
  • SLQT $6.86
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • SLQT 54.86
  • MLYS 50.79
  • Support Level
  • SLQT $2.25
  • MLYS $13.22
  • Resistance Level
  • SLQT $2.53
  • MLYS $14.35
  • Average True Range (ATR)
  • SLQT 0.10
  • MLYS 0.73
  • MACD
  • SLQT 0.04
  • MLYS 0.02
  • Stochastic Oscillator
  • SLQT 73.47
  • MLYS 81.12

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: